Open access

Lipid–ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

S. Roudi H. Y. Estupiñán O. Saher Cristiana Barradas Emma Inganäs Hoang-Ngoan Le N. Frengen Radosław Grochowski Svetlana Pavlova Robert Månsson Welinder Joel Z. Nordin Annabelle Biscans Pär Matsson R. Zain R. Sandberg Michael Hagemann-Jensen S. el Andaloussi

Sep 2026 · bioRxiv · 0 citations · 59 references

Biology

TL;DR

It is demonstrated that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context-specific lipid design in ASO therapeutic development.

DOI Semantic Scholar

Read PDF

Similar papers

Open access Sep 2026

Phosphatidylserine-Engineered Lipid Nanoparticles Enable Systemic mRNA Delivery to the Central Nervous System

Intravenously administered lipid nanoparticles (LNPs) predominantly accumulate in the liver, limiting mRNA delivery to extrahepatic tissues, particularly the central nervous system (CNS). Here, we report a ligand-free strategy for systemic CNS delivery using phosphatidylserine (PS, 1 mol %)-engineered LNPs, in which...

Jun Hyeong Hong, Jae Hoon Kim, Seung-Yeul Lee et al. · ACS Materials Letters · 0 citations

Review Open access Sep 2026

Next-Generation Liposomal and Nanoparticle-Based Systems for Glioblastoma: Molecular Targeting Strategies to Overcome the Blood–Brain Barrier

Glioblastoma (GBM) remains one of the most lethal and intractable central nervous system malignancies, characterized by aggressive cellular proliferation, profound hypoxia, and an immunosuppressive microenvironment. The primary pharmacokinetic obstacle for systemic interventions is the blood–brain barrier (BBB), which...

Joaquin Fiallo Arroyo, Bernardo Castellón, José E. León-Rojas · International Journal of Mol... · 0 citations

Aug 2026

A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors.

This work presents a metabolically targeted, bioorthogonal-activated delivery strategy to address the selectivity and efficiency limitations of current mRNA medicines, providing a promising platform for precision oncology.

Ming-Zhe Zhang, Chun-Hong Wang, Xiaohan Xu et al. · Journal of the American Chem... · 0 citations

Open access Aug 2026

Esterified Cholesterol Conjugates Enable LNP-Mediated mRNA Delivery to the Blood-Brain Barrier Following Intravenous Administration.

The blood-brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary...

Ze-Ru Tian, Xu Wang, A. Benitez et al. · Advances in Materials · 0 citations

Sep 2026

Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors.

Lipid nanoparticles (LNPs) are the leading non-viral platform for nucleic acid delivery, and the structural design of ionizable lipids critically determines their delivery efficiency and therapeutic potential. Here, a dual-functional ionizable lipid was developed by integrating a vinpocetine-derived neurovascular regul...

Yue-Yue Sun, Dan-Dan Huang, Yue Qing et al. · International journal of pha... · 0 citations

Open access Aug 2026

Optimizing nucleic acid delivery using PF14 peptide and lipid nanoparticle systems

Nucleic acid–based therapeutics are a rapidly expanding class of precision medicines capable of directly modulating gene expression. However, their clinical application is limited by challenges in cellular delivery, including large molecular size, hydrophilicity, and susceptibility to enzymatic degradation. To address...

D. Daniele, Z. Hein, O. Saher et al. · International Journal of Pha... · 0 citations